Rallybio
RLYB | NASDAQ
$15.43
-$0.29 (-1.84%)
At close: Nov 16, 2026, 4:00 PM ET
$15.38
-$0.05 (-0.33%)
After-hours:
Nov 16, 2026, 7:33 PM ET
Rallybio Company Profile
Company profile explainedCompany Profile
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Key Executives
| Name | Position |
|---|---|
| Stephen Uden | Co-Founder, President, Chief Executive Officer & Director |
| Jonathan I. Lieber | Chief Financial Officer & Treasurer |
| Martin W. MacKay | Co-Founder & Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 4 | Filing |
| Oct 29, 2026 | 4 | Filing |
| Oct 28, 2026 | 4 | Filing |
| Oct 28, 2026 | 4 | Filing |
| Oct 27, 2026 | 10-Q | Quarterly Report |
| Oct 26, 2026 | 425 | Filing |
| Oct 26, 2026 | 8-K | Current Report |
| Oct 20, 2026 | 4 | Filing |
| Oct 20, 2026 | 4 | Filing |
| Oct 15, 2026 | EFFECT | Filing |
Rallybio
| Country | United States |
| IPO Date | Jul 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Stephen Uden |
Contact Details
234 Church Street New Haven,
Connecticut 06510 United States
Stock Details
| Ticker Symbol | RLYB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001739410 |
| CUSIP Number | 75120L209 |
| ISIN Number | US75120L2097 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove RLYB